Evolving state policy landscapes nationwide have the potential to impact the medtech industry. The 2026 AdvaMed® State Policy Briefing Series provides timely, practical insights into the rapidly changing policy landscape so you can stay informed and ready to respond. Each briefing will provide updates from AdvaMed® policy leaders and experts on legislative activity and regulatory developments, from data governance to right-to-repair and more.
Whether you are monitoring new proposals or tracking ongoing initiatives, these sessions provide in-depth context. Explore the briefings below to stay current on the state actions influencing medtech policy in 2026 and beyond.
AI
State activity on artificial intelligence in healthcare is accelerating, with growing focus on innovation, infrastructure, and regulatory oversight. In this briefing, Geeta Pamidimukkala, VP, Technical & Regulatory,AdvaMed® and Brian McKenzie, Director of Research, Council of State Governments, discuss the evolving policy landscape. Brian highlights CSG’s AI policy work and competitiveness indicators, while Geeta outlines FDA oversight of AI-enabled medical devices.
As of February 27, 2026
MAHA
MAHA is shaping 2026 agendas, and states are also advancing policies that could impact medtech. From PFAS restrictions to microplastics proposals and adjacent health measures, Maggie Mick and Katherine Tschopp from Multistate provide an overview of the issue and its potential impact on medtech.
As of February 13, 2026
EPR & Right to Repair
States continue to introduce EPR and Right to Repair policies, with implications for packaging, service, and device lifecycle. Joe Rinzel and Katherine Tschopp from Multistate will discuss the 2026 EPR landscape and potential medtech impacts. The AdvaMed® team will also provide an update on the right to repair landscape, our gold standard carve-outs, and what we anticipate in 2026.
As of February 6, 2026
Data Issues
State action on data issues, specifically efforts to restrict the storage or use of data outside the United States, is accelerating. In this briefing, Terry Chang, VP, Assistant General Counsel, and Director, Legal & Medical Affairs at AdvaMed® , will discuss the implications of the growing trend of OUS data bills, the existing federal policy framework, and AdvaMed’s work on the issue. He’ll also cover AdvaMed’s position on comprehensive data privacy bills.
As of January 23, 2026